Aroma Bit Receives Additional Capital Investment Funding From Epson X Investment, Kyocera, and TechAccel Ventures
9.2.2021 09:00:00 EET | Business Wire | Press release
Aroma Bit, Inc., (Representative Director & CEO: Shunichiro Kuroki, headquarters: Chuo-ku, Tokyo), develops and markets compact odor imaging sensors and various related innovative services, has allocated additional shares to third-parties. The purpose of the funding is to acquire growth funds needed for future functionality enhancements of the company’s compact odor sensors and development of mass production capabilities, business development, and etc. EB-GB Limited Partnership funded by Epson X Investment Corporation (Representative Director: Yasunori Ogawa, headquarters: Chiyoda-ku, Tokyo), Kyocera Corporation (President: Hideo Tanimoto, headquarters: Kyoto City, Kyoto), and TechAccel investment limited partnership 1 (fund operated by TechAccel Ventures, LLC (Functional Manager: Masatoshi Ohba, headquarters: Minato-ku, Tokyo)) are the investment partners participating in this new capital investment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005274/en/
Silicon CMOS type Smell Sensor Development Kit (Product ID: 5C-SSM) (Photo: Business Wire)
Aroma Bit, Inc.: http://www.aromabit.com
Purpose and background of the increased capital investment: Support for acceleration of the compact odor sensors’ mass production and expansion of the digital odor sensing market
Aroma Bit has developed the world’s first compact odor imaging sensor that digitizes odors with visualization patterns from various odor inputs, similar to an animal’s sense of smell. It differs from conventional gas sensors, which can only detect specific substances.
Despite COVID-19, Aroma Bit has seen an increase in business negotiations with customers both in Japan and internationally accelerated by emerging trends such as smart technology, contactless technology, and digital transformation (DX).
Furthermore, the device has a wide range of applications, including the food, agriculture, daily commodities, industrial machinery, mobility, healthcare, robotics, mobile information service, home electronics, and IoT industries. With market applications exceeding initial expectations, there is considerable potential demand for odor digitization using Aroma Bit’s innovative technology.
After this third-party allocation of new shares, Aroma Bit plans to collaborate with major electronic device companies with advanced manufacturing expertise to accelerate development and mass production of compact odor sensor technologies.
Additionally, Aroma Bit plans to strengthen development of new products and services that leverage the company’s proprietary odor databases, and expand its sales and marketing worldwide.
In the future, Aroma Bit will continue to pursue its vision of “Enrich Society by Creating a World where Odors and Aromas are Visualized through Digital Odor Sensing Technology.”
Release of development kit for silicon CMOS compact odor sensors
Aroma Bit launched its silicon CMOS sensor module development kit [5C-SSM-H1] in January of 2021. Those sensors feature 80 elements arranged on a 6 mm x 3 mm silicon chip (5 types of odor-sensitive membrane x 16 elements per membrane). Aroma Bit Silicon Sensor Technology, Inc., a subsidiary of Aroma Bit manages sales for these devices.
With the release of the silicon CMOS odor sensor, Aroma Bit anticipates increased demand in high-volume consumer applications such as mobile devices, mobility, and home electronics, where its other QCM odor sensor use was previously difficult due to factors such as price and usage environment.
About Aroma Bit
Aroma Bit is a company that plans, develops, and sells electronic devices such as compact odor sensors as well as innovative new services that use these devices.
|
[Company Profile] |
||
|
Company name: |
|
Aroma Bit, Inc. |
|
Location: |
|
Sagami Bldg. 2F, 7-13-6 Ginza, Chuo-ku, Tokyo |
|
Representative: |
|
Representative Director & CEO Shunichiro Kuroki |
|
Established: |
|
February 2014 |
|
Business: |
|
Development, production, and sales of electronic equipment and systems including compact odor imaging sensors |
|
|
|
Planning, development, and sales of products and innovative services that use the sensor products |
|
|
|
Other business related to the above |
|
URL: www.aromabit.com |
||
About Epson X Investment
Epson X Investment Corporation is a Corporate Venture Capital (CVC) firm wholly owned by information equipment and precision instrument manufacturer Seiko Epson Corporation. It established the “EP-GB Investment Limited Partnership” with independent venture capital firm Global Brain Corporation, which has strengths in CVC operations, as general partner and is conducting investment activities.
URL: https://www.epson-exi.com/
Kyocera Corporation (TOKYO:6971, https://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2020, the company’s consolidated sales revenue totaled 1.6 trillion yen (approx. US$14.7 billion). Kyocera is ranked #549 on Forbes magazine’s 2020 “Global 2000” list of the world’s largest publicly traded companies.
About TechAccel Ventures
TechAccel Ventures, LLC is a venture capital firm established and operated by Omron, Ricoh, and SMBC Venture Capital. It invests mainly in tech venture companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005274/en/
Contact information
[Inquiries regarding this announcement]
Aroma Bit, Inc.
Public Relegations Department (Matsumoto, Osamu)
TEL: +81-3-4455-4609 / Email: info@aromabit.com
Epson X Investment Corporation
Seiko Epson PR & IR Department (Muto, Nobuo)
TEL: +81-266-58-1705 or +81-3-5368-0961 / Email: info@press.epson.co.jp
KYOCERA Corporation
Corporate Communications (Usami, Masaru)
TEL: +81-75-604-3514 / Email: webmaster.cc@kyocera.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom